Recursion Pharmaceuticals (RXRX) director sells 30,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. director Blake Borgeson completed an open-market sale of 30,000 shares of Class A Common Stock at $3.52 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025. Following this sale, Borgeson directly owns 6,199,863 shares of Class A Common Stock, so the transaction represents a small portion of his overall reported holdings.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares ($105,600)

Net Sell 1 txn

Insider Borgeson Blake

Role null

Sold 30,000 shs ($106K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	30,000	$3.52	$106K

Holdings After Transaction: Class A Common Stock — 6,199,863 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 30,000 shares Sale price: $3.52 per share Shares owned after sale: 6,199,863 shares

3 metrics

Shares sold 30,000 shares Open-market sale of Class A Common Stock

Sale price $3.52 per share Price for the 30,000-share open-market sale

Shares owned after sale 6,199,863 shares Direct holdings following the transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/05/2026		S(1)		30,000	D	$3.52	6,199,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RXRX director Blake Borgeson report?

Blake Borgeson reported an open-market sale of 30,000 shares of Recursion Pharmaceuticals Class A Common Stock at $3.52 per share. This Form 4 filing shows a routine disposition while he continues to hold 6,199,863 shares directly after the transaction.

At what price did Blake Borgeson sell Recursion Pharmaceuticals (RXRX) shares?

He sold 30,000 shares of Recursion Pharmaceuticals Class A Common Stock at $3.52 per share. This price reflects the execution level for the reported open-market sale and is disclosed as the transaction price in the Form 4 filing.

How many RXRX shares does Blake Borgeson own after this Form 4 sale?

After the reported sale, Blake Borgeson directly owns 6,199,863 shares of Recursion Pharmaceuticals Class A Common Stock. This post-transaction balance indicates that the 30,000 shares sold are a relatively small fraction of his disclosed holdings.

Was Blake Borgeson’s RXRX share sale made under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Blake Borgeson on August 31, 2025. Such plans allow pre-scheduled trades, signaling that the timing was set in advance.

What type of security did Blake Borgeson sell in Recursion Pharmaceuticals (RXRX)?

He sold Class A Common Stock of Recursion Pharmaceuticals. The Form 4 reports a non-derivative transaction involving 30,000 shares of this class, executed as an open-market sale at a price of $3.52 per share.